Clinical trials: Depression Symptom
Depression, Anxiety, Mental Health Issue
Clinical Outcomes of a Digital Mental Health Intervention for Moderate/Severe Depression and Anxiety
A digital mental health intervention (BetterHelp, Mountain View, CA) provides users with access to online therapy care for treatment of depression and anxiety.
- Conditions
- Depression, Anxiety, Mental Health Issue, Mental Health Wellness 2
- Trial name
- NCT07081061
- Testing
- BetterHelp
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Teladoc Health
Depression, Anxiety
Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of…
- Trial name
- NCT02411123
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- AltheaDx
Depression
Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients.
- Trial name
- NCT00672659
- Testing
- Citalopram + Pipamperone, Citalopram
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- PharmaNeuroBoost N.V.
Major Depressive Disorder
Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of three fixed dosages of Lu AA34893 compared to placebo in the treatment of patients with Major Depressive Disorder.
- Trial name
- NCT00766870
- Testing
- Lu AA34893, Venlafaxine extended release
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
The purpose of this study is to evaluate the impact of escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom.
- Trial name
- NCT01870843
- Testing
- Escitalopram
- Where
- 10 sites in China
- Volunteers
- 261 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Depression/Anxiety
Comparison of Vocal Biomarkers for Depression and Anxiety to Formal Clinical Assessments
Participants will be recruited to complete self reported surveys normally used as standards of care for screening and monitoring depression and anxiety symptom severity, provide a voice sample composed of an answer to open ended…
- Trial name
- NCT06464575
- Where
- United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Ellipsis Health
Depressive Disorder, Major
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing…
- Trial name
- NCT03185819
- Testing
- Midazolam, Esketamine
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 147 people
- Sponsor
- Janssen Research & Development, LLC
Mental Health, Depression
Viome Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions
US residents who have mental health issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms.
- Conditions
- Mental Health, Depression, Anxiety
- Trial name
- NCT05563857
- Testing
- VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Viome
Drug Overdose, Opioid-Related Disorders
Development of an Algorithm That Predicts Hypoventilation Due to an Opioid Overdose
RTM Vital Signs, LLC is developing a miniature wearable tracheal sound sensor that communicates with a cell phone containing a machine-learning diagnostic algorithm designed to detect and predict the onset of mild, moderate, and…
- Trial name
- NCT03845699
- Testing
- Diagnostic algorithms that detects/predicts hypoventilation
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RTM Vital Signs, LLC
Major Depressive Disorder
Dose-finding Study With Lu AA24530 in Major Depressive Disorder
The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo
- Trial name
- NCT00599911
- Testing
- Lu AA24530, Duloxetine
- Where
- 72 sites in Australia, Austria and 15 more
- Volunteers
- 652 people
- Sponsor
- H. Lundbeck A/S
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Major Depressive Disorder
An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
The primary objective of this study is to evaluate the efficacy of 3 fixed doses of SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major Depressive Disorder (MDD), based on the 17-item Hamilton…
- Trial name
- FIDELIO (NCT00822744)
- Testing
- SSR411298, Escitalopram
- Where
- 7 sites in Chile, Mexico and 5 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Major Depressive Disorder, Anhedonia
PD, PK, and Safety of ALTO-203 in Patients With MDD
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period.
- Trial name
- NCT06391593
- Testing
- ALTO-203 25 μg, ALTO-203 75 μg
- Where
- 15 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alto Neuroscience
Depression
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese heathy subjects.
- Trial name
- NCT03456388
- Testing
- Ammoxetine Hydrochloride Enteric-coated Tablets
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Depression
A Study of RO4917523 in Patients With Treatment Resistant Depression
This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison to placebo, in patients with treatment-resistant depression.
- Trial name
- NCT00809562
- Testing
- RO4917523
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Anxiety, Microbiome
Microbiome, Anxiety and Cognitive Orientation Study
Mounting evidence shows that the gut microbiome plays an important role in communication within the gut-brain axis. However, the relationship between gut microbiota and their influence on anxiety is still not fully understood.
- Conditions
- Anxiety, Microbiome, Mood Disorders, Neurodegeneration
- Trial name
- MACO (NCT05388630)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Endominance
Treatment Resistant Depression
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major…
- Trial name
- NCT06524830
- Testing
- VLS-01-203 BU
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 142 people
- Sponsor
- atai Therapeutics, Inc.
Major Depressive Disorder
Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
The objectives of this study were to examine the cardiovascular sensitivity to oral tyramine after establishment of steady state with CX157 Modified Release (MR) Tablets, 125 mg administered twice per day (BID) in healthy…
- Trial name
- CX157-112 (NCT01633437)
- Testing
- CX157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CeNeRx BioPharma Inc.
Depression, Schizophrenia
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
This is a research study comparing the safety and efficacy of two active study medications
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00034801
- Testing
- olanzapine, ziprasidone
- Where
- 30 sites in United States
- Volunteers
- 378 people
- Sponsor
- Eli Lilly and Company
Parkinson Disease
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
The objective of this PMS study is the evaluation of depressive symptoms measured with Unified Parkinson's Disease Rating Scale (UPDRS) Part I (mentation, behavior and mood) and with Hospital Anxiety and Depression Scale…
- Trial name
- NCT00651183
- Testing
- Pramipexole immediate release
- Where
- 57 sites in Austria
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim